Growth Hormone Peptide in Oncology: Clinical Evaluation of Safety

GROWTH hormone secretagogues raise physiological growth factors, demanding vigilant clinical evaluation regarding potential oncologic risks.

Oncologic Concerns with Growth Hormone Secretagogues

Therapeutic strategies utilizing growth hormone secretagogues are designed to stimulate endogenous, pulsatile growth hormone release through the pituitary and hypothalamus while preserving endogenous negative feedback. Although these agents circumvent the persistent supratherapeutic hormone concentrations linked to exogenous recombinant growth hormone administration, their downstream endocrine actions warrant scrutiny in clinical oncology. Secretagogue administration directly augments systemic levels of growth hormone and insulin-like growth factor 1, producing downstream endocrine signaling that stimulates peripheral tissues. Within oncology practice, prolonged exposure to elevated insulin-like growth factor 1 remains a recognized factor in promoting cell survival, cellular proliferation, and mitogenesis. Preclinical evidence has long identified heightened circulating insulin-like growth factor 1 as a contributor to advanced prostate cancer progression and other malignancies, raising questions about whether secretagogue therapy poses comparable risks. Because growth hormone secretagogues elevate circulating insulin-like growth factor 1 across both adult and pediatric populations, defining the long-term oncologic safety profile of these agents is critical.

Clinical Evidence Gaps and Patient Surveillance

Despite extensive investigation into short-term endpoints such as growth velocity, nitrogen retention, and body composition, rigorous clinical trials examining long-term outcomes remain scarce. Current published studies of growth hormone secretagogues have evaluated small cohorts over restricted intervals, leaving cancer incidence and overall mortality uncharacterized in human populations. In addition to potential mitogenic concerns linked to elevated growth factors, clinical investigations demonstrate reproducible decreases in insulin sensitivity and subsequent rises in fasting blood glucose and hemoglobin A1c. Impaired glucose homeostasis, coupled with the absence of multiyear oncologic surveillance data, necessitates careful multidisciplinary evaluation when considering these agents in patients with personal or family histories of neoplasia. Clinicians evaluating patients receiving growth hormone secretagogues should implement routine monitoring of serum insulin-like growth factor 1, comprehensive metabolic panels, and diligent oncologic screening until definitive, multiyear safety trials clarify long-term malignancy outcomes.

Reference

Sigalos JT et al. The Safety and Efficacy of Growth Hormone Secretagogues. Sex Med Rev. 2018;6(1):45-53.